Objective:The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment in the patients with advanced non-small-cell lung cancer (NSCLC).Methods:Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups.In docetaxel group (DP group) the patients received docetaxel 75 mg/m 2 and cisplatin 60mg/m 2 on day 1.In gemcitabine group (GP group) the patients received gemcitabine 1000mg/m 2 on day 1 and day 8.The dosage of cisplatin was the same as DP group.The two regiments were administrated intravenously every 21 days as a cycle,each patient received 2-4 cycles.All patients were followed up until disease progressed or patients died.Results:The overall response rates were 43.5% in DP group and 45.9% in GP group.The response rate was significantly different between the initial treated group and retreated group in both two groups (53.8% vs 23.0% in DP group and 56% vs 25% in GP group,P<0.05,respectively).The main side effects were bone marrow suppression and thrombocytopenia.Conclusion:Docetaxel/cisplatin regiment and gemcitabine/cisplatin regiment for the patients with advanced NSCLC were efficient and well-tolerated chemotherapeutic approachs with low toxicity levels.The efficacy and major toxicity in two groups were similar. Objective: The aim of this study was to evaluate the clinical efficacy and side effects of docetaxel / cisplatin regiment and gemcitabine / cisplatin regiment in the patients with advanced non-small-cell lung cancer (NSCLC). Methods: Seventy-six patients with advanced NSCLC who were chemotherapy-naive were enrolled in two groups. Docetaxel group (DP group) the patients received docetaxel 75 mg / m 2 and cisplatin 60 mg / m 2 on day 1. In gemcitabine group (GP group) the patients received gemcitabine 1000 mg / m 2 on day 1 and day 8.The dosage of cisplatin was the same as DP group. The two regiments were administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients werefol up until disease progressed or patients died. Results: The overall response rates were 43.5% in DP group and 45.9% in GP group. The response rate was significantly different between the initial treated group and retreated group in both two groups (53.8% vs 23.0% in DP group and 56% vs 25% in G P group, P <0.05, respectively). The main side effects were bone marrow suppression and thrombocytopenia. Conlusion: Docetaxel / cisplatin regiment and gemcitabine / cisplatin regiment for the patients with advanced NSCLC were efficient and well-tolerated chemotherapeutic approaches with low toxicity levels The efficacy and major toxicity in two groups were similar.